Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission

In December 2022, Representative Jamie Raskin (D-MD) shared with the public that he had been diagnosed with diffuse large B-cell lymphoma (DLBCL). Although being diagnosed with cancer can be frightening, Rep. Raskin remained in good spirits, sharing that his condition was treatable and even curable. Luckily, Rep. Raskin was correct. CNN reported in April 2023 that, after undergoing chemotherapy, Rep. Raskin is now in remission. The member of the House Oversight Committee also shared that doctors told him that he only has around a 10% chance of relapse. 

What is Diffuse Large B-Cell Lymphoma (DLBCL)?

Diffuse large B-cell lymphoma is the most common form of fast-growing non-Hodgkin’s lymphoma (NHL), a type of cancer that forms in the body’s lymphatic system. Normally, the lymphatic system plays a role in immune health; white blood cells called lymphocytes help fight infection. In DLBCL, cancer forms in abnormal B-lymphocytes. This aggressive cancer is most common in people aged 65+. Having an autoimmune disease, a family history of DLBCL, or a weakened immune system also raise the risk of developing this cancer. 

Initially, many individuals with DLBCL may notice painless lymph node inflammation in various areas throughout the body such as the neck, armpit, groin, testicles, or abdomen. In around 40% of patients, DLBCL occurs in extranodal form, or beyond the lymph nodes. As the cancer progresses, other symptoms may appear. These may differ based on the affected part of the body. Potential symptoms may include:

  • Unintentional weight loss
  • Itchy skin
  • Appetite loss
  • Fever and drenching night sweats
  • Cough or breathlessness
  • Abdominal discomfort
  • Diarrhea and/or bloody stool 

Treatment also varies based on the cancer’s stage, where the cancer is located, overall health, symptoms, and possibility of remission. Doctors may encourage patients to undergo chemotherapy, immunotherapy, bone marrow transplantation, radiation, or surgical interventions to treat their cancer. An estimated 60-80% of people survive at least 5 years or more following diagnosis. If you have DLBCL, please speak with your care team to determine your best course of treatment. 

Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Share this post

Follow us